AmVac (Switzerland) a development-stage vaccine company focused on vaginitis , BPH and RSV, closed a $2.8M Series A financing bringing the total round to $4M. Participants include Venture+ and Co Fonds 2.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Lumavita (Switzerland) a clinical-stage biopharmaceutical company focused on anti-infectives for women’s health including vaginitis, HPV and HSV, closed a $5.5 Series A bring the total round up to $22M. Participants include HealthCap and Endeavour Vision.